0001127602-22-008498.txt : 20220307 0001127602-22-008498.hdr.sgml : 20220307 20220307174927 ACCESSION NUMBER: 0001127602-22-008498 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220303 FILED AS OF DATE: 20220307 DATE AS OF CHANGE: 20220307 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Spurr Robert CENTRAL INDEX KEY: 0001543795 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 22719552 MAIL ADDRESS: STREET 1: C/O BAUSCH HEALTH COMPANIES INC. STREET 2: 400 SOMERSET CORPORATE BLVD. CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bausch Health Companies Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: Valeant Pharmaceuticals International, Inc. DATE OF NAME CHANGE: 20100928 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2022-03-03 0000885590 Bausch Health Companies Inc. BHC 0001543795 Spurr Robert C/O BAUSCH HEALTH COMPANIES, INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 1 U.S. President-Pharma Business Common Shares, No Par Value 2022-03-03 4 F 0 4074 23.61 D 96947 D This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Due to an inadvertent administrative error, the reporting person previously filed a Form 4 on March 2, 2022 reporting the vesting of performance-based Restricted Share Units ("PSUs") on February 27, 2022. The Issuer's Talent and Compensation Committee of the Board certified the performance goals applicable to these PSUs on February 14, 2022, which was the correct date on which these PSUs performance-vested. /s/ Debra E. Levin, attorney-in-fact for Robert A. Spurr 2022-03-07